JPRN-UMIN000010181已完成2 期
Optimal administration of fosaprepitant in patients with colon cancer - Administration of fosaprepitant to colon cancer patients
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who previously developed serious or irreversible adverse effects at the administration site 2) Patients who were judged to be inappropriate as subjects by the study investigators
研究者
相似试验
已完成
2 期
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)Chemotherapy-induced Nausea and VomitingNCT01697579Merck Sharp & Dohme LLC240
招募中
2 期
The efficacy of fosaprepitant to the moderate emetic risk intravenous chemotherapyPatients who are not effective by two antiemetic drugs(5-HT3 antagonist and dexamethasone) for the moderate emetic risk intravenous chemotherapy(L-OHP, CPT-11, CBDCA)JPRN-UMIN000009311Division of Clinical Oncology, Tohoku University Hospital50
终止
2 期
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell CarcinomaChemotherapy-induced Nausea and VomitingNCT01874119St. Louis University13
进行中（未招募）
Unknown
Safety of a short-term infusion of fosnetupitantSolid tumorJPRN-jRCT1041220144arita Yukiya70
终止
3 期
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)Chemotherapy-induced Nausea and VomitingNCT02519842Merck Sharp & Dohme LLC75